同时降低胆固醇和cGAS-STING路径放大:一种针对瘤抵抗的新型酶级联策略
Chenxin Liu1, Jialing Guo1, Jieke Zhang1
1School of Pharmaceutical Sciences, Zhengzhou University, 100 Science Road, Zhengzhou, Henan 450001, China.
ACS applied materials & interfaces
|June 6, 2025
概括
这项研究引入了DOX@CM@M纳米颗粒,通过削减胆固醇和激活天生的免疫力来克服癌症药物耐药性. 这种新的方法提高了化疗的疗效,并增强了抗瘤免疫反应,以改善癌症治疗.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
- 癌症治疗 癌症治疗
背景情况:
- 抗药性在癌症治疗中是一个主要的挑战,通常涉及P-glycoprotein (P-gp) 抑制剂.
- 瘤细胞膜的刚性和免疫抑制性瘤微环境限制了目前的治疗疗效.
研究的目的:
- 开发一种新的纳米粒子平台 (DOX@CM@M),以逆转瘤耐药性并增强抗瘤效果.
- 研究胆固醇消耗和天生的免疫激活作为改善癌症治疗的机制.
主要方法:
- 使用Fe/Mn混合金属有机框架 (MOF) 来封装多克索鲁比 (DOX) 和胆固醇氧化酶 (COD).
- 改造的纳米粒子与癌细胞膜 (CCM) 增强瘤向.
- 利用酸性和富含GSH的瘤环境进行响应性纳米粒子降解.
主要成果:
- DOX@CM@M纳米粒子有效地降低了胆固醇,促进了DOX的积累,并逆转了药物耐药性.
- 激活了cGAS-STING通路,被Mn2+放大,增强了天生的免疫反应.
- 显著抑制瘤生长,降低胆固醇水平,并在体内促进DC成熟.
结论:
- DOX@CM@M纳米粒子为克服癌症抗药性提供了一个有希望的策略.
- 胆固醇消耗和免疫激活协同增强治疗结果.
- 该平台提出了一种改善癌症治疗疗效的新方法.
更多相关视频
13:38Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
12.4K
10:13A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
11.3K
相关概念视频
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Interactions Between Signaling Pathways
6.6K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
